Related Experiment Videos
Effects of neuroleptics on platelet monoamine oxidase activity
Abstract:
Platelet MAO activity in schizophrenics was significantly decreased, by about 15%, after 3 weeks of treatment with haloperidol. Treatment with thioridazine or butaperazine also tended to decrease platelet MAO activity. The neuroleptic-induced decrease began to appear within a few days of treatment and did not show tolerance over 1-2 months of treatment with haloperidol. Platelet MAO activity of schizophrenic patients measured during drug-free base-line was not significantly different from that of normal controls, but MAO activity of schizophrenics was significantly lower than normals after 3 weeks of treatment with neuroleptics. The extent of decrease in platelet MAO activity correlated negatively with base-line prolactin and its increase after 24 hr. With PEA as substrate, the decrease in activity correlated positively with steady state plasma haloperidol.
Insights
Antipsychotic medications like haloperidol significantly decrease platelet monoamine oxidase (MAO) activity in schizophrenia patients. This reduction occurs within days and persists, offering potential biomarkers for treatment response.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a complex psychiatric disorder with debated neurobiological underpinnings.
- Platelet monoamine oxidase (MAO) activity has been investigated as a potential biomarker in psychiatric conditions.
- Previous research on MAO activity in schizophrenia has yielded inconsistent results.
Purpose of the Study:
- To investigate the effect of neuroleptic treatment on platelet MAO activity in patients with schizophrenia.
- To determine if neuroleptic-induced changes in MAO activity correlate with clinical or biochemical markers.
Main Methods:
- Platelet MAO activity was measured in schizophrenic patients before and during treatment with haloperidol, thioridazine, or butaperazine.
- Measurements were taken at baseline, after 3 weeks, and up to 1-2 months of treatment.
- Correlations were analyzed between MAO activity changes and baseline/post-treatment prolactin levels and plasma haloperidol concentrations.
Main Results:
- Neuroleptic treatment, particularly haloperidol, significantly decreased platelet MAO activity by approximately 15% after 3 weeks.
- This decrease was observed within days of treatment initiation and showed no tolerance over 1-2 months.
- Baseline MAO activity did not differ between schizophrenic patients and normal controls, but treated schizophrenics showed significantly lower activity than normals.
- The extent of MAO decrease correlated negatively with baseline prolactin and its 24-hour increase, and positively with plasma haloperidol levels (using PEA as substrate).
Conclusions:
- Neuroleptic medications effectively reduce platelet MAO activity in schizophrenia patients.
- This reduction is a consistent finding, appearing early in treatment and persisting over time.
- Platelet MAO activity changes may serve as a pharmacodynamic marker for neuroleptic treatment in schizophrenia, potentially correlating with drug levels and hormonal responses.